2
|
Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E, Sala G, Tillner J, Malik R, Baselga J. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Salazar
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - J. Tabernero
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - F. Rojo
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - E. Jimenez
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - I. Montaner
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - E. Casado
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - G. Sala
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - J. Tillner
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - R. Malik
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| | - J. Baselga
- Hospital Vall d′Hebron, Barcelona, Spain; Merck Farma y Química, SA, Barcelona, Spain; Merck KGaA, Darmstadt, Germany
| |
Collapse
|
3
|
Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, Pfeifer W, Mueser M, Montaner I, Gatzemeier U. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7012] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Rosell
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - C. Daniel
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - R. Ramlau
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - A. Szczesna
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - M. Constenla
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - B. Mennecier
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - W. Pfeifer
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - M. Mueser
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - I. Montaner
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| | - U. Gatzemeier
- Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Chu Morvan, Institut de Cancerologie, Brest, France; Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Poznan, Poland; Mazowieckie Centrum Chorob Pluc i Gruzlicy, Otwock, Poland; Hospital de Pontevedra, Pontevedra, Spain; Hopitaux Universitaires, Strasbourg, France; A o Krankenhaus d. Stadt Linz, Linz, Austria; Merck KGaA, Darmstadt, Germany; Grosshansdorf Hospital, Grosshansdorf, Germany
| |
Collapse
|